Drug Trial Radar · NCT06920771
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
691
Actual
Start
Sep 9, 2024
Primary completion
Mar 30, 2026
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- HAL AllergyIndustry
- Sponsor type
- Industry
- Collaborators
- Ergomed; ClinCompetence Cologne GmbH
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust mites (HDM)-induced allergic rhinitis/rhinoconjunctivitis. This Phase 3 clinical study aims to demonstrate the effecacy of PURETHAL Mites (PM) Mixture subcutaneous immunotherapy (SCIT) compared to a placebo over one year of treatment in patients with moderate to severe HDM- induced allergic rhinitis/rhinoconjunctivitis (ARC), while also prioritizing the safety of the treatment. PM Mixture is a suspension of chemically modified extract from the house dust mites Dermatophagoides pteronyssinus (D. pter) and Dermatophagoides farinae (D. far), adsorbed to aluminium hydroxide. Modified extracts (allergoids) are associated with reduced allergenicity but with preserved immunogenicity. Based on the previous studies the dose of 0.5 mL of PM Mixture solution with concentration 50,000 AUeq/mL (allergen units in millilitre) was selected for this Phase 3 clinical study. Objectives: The primary objective is to assess the efficacy of PM Mixture 50,000 AUeq/mL (0.5 mL) SCIT based on an average Total Combined Rhinitis Score (TCRS), which will be compared between PM Mixture and placebo groups. The TCRS consists of rhinitis symptom score and medication score measured daily over the last 8 weeks of the 1 year treatment. Other secondary efficacy parameters will be compared between treatment groups to show efficacy: rhinitis symptom and medication scores separately as well as a combined symptom and medication score for nasal symptoms only (CSMS(n)); Total Combined Conductivities Score; nasal provocation test; immunological blood markers such as immunoglobulins E, G and G4; and Rhinitis Quality of Life Questionnaire (standardised) (RQLQ(S)). Trial design: This is a randomized, double-blind, placebo controlled multi-centre clinical trial where subjects are participating for about 14 months. Trial population: Patients (18-65 years of age) suffering from moderate to severe ARC induced by HDM with or without controlled asthma can be included in the study. The main criteria to evaluate the HDM allergy will be done by the following parameters: allergic medical history to HDM minimum 1 year; positive skin prick test and nasal provocation test HDM D. pter and/or D. far; certain level of allergen-specific immunoglobulin E to D. pter or D. far, and most importantly they should have sufficient rhinitis symptom score measured during 2 weeks at screening. Additionally patients should have sufficient lung functions confirmed by the spirometry, they may have asthma which should be controlled. Patients with a chronic or acute disease that might place the subject at an additional risk will not be included. Certain medications which can interfere with the study treatment or increase the health risks should be washed-out and can not be taken during the study. Approximately 920 HDM-allergic subjects will be screened in order after the screening period to enroll 552 subjects.
Conditions
- House Dust Mite Allergy
- House Dust Mite Rhinitis
Interventions
PURETHAL Mites 50,000 AUeq/mlBiological
Biological/Vaccine: Placebo Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals
Biological/Vaccine: PlaceboBiological
Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectiveTime frame: Last 8 weeks (before end of study) of the intervention.
Locations
68 sites in 5 countries. Site status is shown where the registry gives one.
UMBAL Kaspela
Plovdiv, Bulgaria
Medical Center Prolet EOOD
Rousse, Bulgaria
Medical Center Smolyan
Smolyan, Bulgaria
DCC Convex
Sofia, Bulgaria
Diagnostic-Consulativ Senter Ascendent
Sofia, Bulgaria
University Hospital Alexandrovska
Sofia, Bulgaria
Emovis GmbH
Berlin, Germany
Praxis Dr. Ginko
Bonn, Germany
Praxis Dr. Elke Decot
Dreieich, Germany
HNO-Praxis Dr. Udo Schäfer
Dresden, Germany
HNO Praxis Dr. Uta Thieme
Duisburg, Germany
Medizentrum Essen-Borbeck
Essen, Germany
Pneumologisches Forschungsinstitut Hohegeest GbR
Geesthacht, Germany
HNO-Facharztpraxis Alte Post
Göttingen, Germany
HNO Research GmbH
Itzehoe, Germany
Hospital Schleswig-Holstein. Klinik für Dermatologie, Venerologie und Allergologie.
Kiel, Germany
BAG Prof. G. Hoheisel/Dr. A. Bonitz Praxis für Pneumologie und Allergologie - Studienzentrum
Leipzig, Germany
Praxis Dr. Bohn
Mittweida, Germany
Ballenberger, Freytag, Wenisch -Institut für klinische Forschung GmbH
Neu-Isenburg, Germany
Studienzentrum MOL BAG Dres. E.Hippke & S. Runge
Neuenhagen, Germany
KliFOs - Klinische Forschung Osnabrück
Osnabrück, Germany
Studienzentrum Dr.Schlenska
Peine, Germany
Studienzentrum Dr.Laßmann
Saalfeld, Germany
Allergo GmbH - Prüfzentrum Schorndorf
Schorndorf, Germany
Klinikum Stuttgart - Krankenhaus Bad Cannstatt
Stuttgart, Germany
LOR Clinic
Riga, Latvia
The Center of Investigation in Treatment of Allergyc Diseases
Riga, Latvia
CD8 clinic
Kaunas, Lithuania
Lithuanian University of Health Sciences Kauno klinikos
Kaunas, Lithuania
Inovatyvios alergologijos centras
Vilnius, Lithuania
JSC Center for Diagnosis and Treatment of Allergic Diseases
Vilnius, Lithuania
JSC Family Doctor
Vilnius, Lithuania
JSC Inlita
Vilnius, Lithuania
JSC Verkiu clinic
Vilnius, Lithuania
NZOZ Homeo Medicus Poradnia Alergologiczna
Bialystok, Poland
Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny Anna Płoszczuk
Bialystok, Poland
Specjalistyczna Praktyka Lekarska AlerMedica
Bialystok, Poland
Centrum Medyczne KERmed
Bydgoszcz, Poland
Pratia - Ośrodek Badań Klinicznych
Częstochowa, Poland
Clinica Vitae Spółka z o. o.
Gdansk, Poland
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.